Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Other Non-Current Liabilities (2016 - 2023)

Corbus Pharmaceuticals Holdings has reported Other Non-Current Liabilities over the past 6 years, most recently at $44000.0 for Q4 2023.

  • For Q4 2023, Other Non-Current Liabilities rose 98.15% year-over-year to $44000.0; the TTM value through Dec 2023 reached $44000.0, up 98.15%, while the annual FY2023 figure was $44000.0, 98.15% up from the prior year.
  • Other Non-Current Liabilities for Q4 2023 was $44000.0 at Corbus Pharmaceuticals Holdings, down from $44410.0 in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $2.5 million in Q1 2023 and troughed at $797.0 in Q4 2020.
  • A 4-year average of $328741.7 and a median of $22205.0 in 2021 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 97.23% in 2022 and later surged 11258.73% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $797.0 in 2020, then soared by 2686.07% to $22205.0 in 2021, then changed by 0.0% to $22205.0 in 2022, then skyrocketed by 98.15% to $44000.0 in 2023.
  • Business Quant data shows Other Non-Current Liabilities for CRBP at $44000.0 in Q4 2023, $44410.0 in Q3 2023, and $22205.0 in Q2 2023.